Luminex Corp.

Luminex develops, manufactures and sells biological testing technologies and products with applications in the life sciences industries, including diagnostics, pharmaceutical and research. The company delivers its products to various market segments, including multiplexing, reduction of labor and ability to test for proteins and nucleic acids. The company's products include: instruments, which include Luminex? 100/200?, FLEXMAP? 3D, MAGPIX?, ARIES?, and ARIES? M1; consumables, which include MicroPlex? Microspheres, MagPlex? Microspheres, and xTAG? Microspheres; software, which includes xPONENT?, TDAS?, SYNCT?, and IDEAS?; and clinical diagnostic assay product families, which include ARIES? Cassettes.
  • TickerLMNX
  • ISINUS55027E1029
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
LMNX LUMINEX CORP. (Health Care)

LUMINEX sees a downgrade to Slightly Negative on account of less funda...

The independent financial analyst theScreener just lowered the general evaluation of LUMINEX (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date April 6, 2021, the closing price was USD 31.81 and its target price was estimated at USD 23.09.

LMNX LUMINEX CORP. (Health Care)

Luminex Corp: 3 directors sold after exercising options/sold

Three Directors at Luminex Corp sold after exercising options/sold 88,462 shares at between 39.021USD and 40.160USD. The significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is ...

LMNX LUMINEX CORP. (Health Care)

LUMINEX sees a downgrade to Slightly Negative on account of less funda...

The independent financial analyst theScreener just lowered the general evaluation of LUMINEX (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date April 6, 2021, the closing price was USD 31.81 and its target price was estimated at USD 23.09.

LMNX LUMINEX CORP. (Health Care)

Luminex Corp: 3 directors sold after exercising options/sold

Three Directors at Luminex Corp sold after exercising options/sold 88,462 shares at between 39.021USD and 40.160USD. The significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is ...

LMNX LUMINEX CORP. (Health Care)

LUMINEX sees a downgrade to Slightly Negative on account of less funda...

The independent financial analyst theScreener just lowered the general evaluation of LUMINEX (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date April 6, 2021, the closing price was USD 31.81 and its target price was estimated at USD 23.09.

LMNX LUMINEX CORP. (Health Care)

Luminex Corp: 3 directors sold after exercising options/sold

Three Directors at Luminex Corp sold after exercising options/sold 88,462 shares at between 39.021USD and 40.160USD. The significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is ...

LMNX LUMINEX CORP. (Health Care)

LUMINEX sees a downgrade to Slightly Negative on account of less funda...

The independent financial analyst theScreener just lowered the general evaluation of LUMINEX (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date April 6, 2021, the closing price was USD 31.81 and its target price was estimated at USD 23.09.

LMNX LUMINEX CORP. (Health Care)

Luminex Corp: 3 directors sold after exercising options/sold

Three Directors at Luminex Corp sold after exercising options/sold 88,462 shares at between 39.021USD and 40.160USD. The significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is ...

LMNX LUMINEX CORP. (Health Care)

LUMINEX sees a downgrade to Slightly Negative on account of less funda...

The independent financial analyst theScreener just lowered the general evaluation of LUMINEX (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date April 6, 2021, the closing price was USD 31.81 and its target price was estimated at USD 23.09.

LMNX LUMINEX CORP. (Health Care)

Luminex Corp: 3 directors sold after exercising options/sold

Three Directors at Luminex Corp sold after exercising options/sold 88,462 shares at between 39.021USD and 40.160USD. The significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch